Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (151-160 of 336) with videos related to

Pageof 34
Sort By:
European Urology Oncology|August 13, 2023
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysisCarlo Messina, Emilio Francesco Giunta, Alessio Signori, et al.
Acta Bio-Medica : Atenei Parmensis|January 8, 2020
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumabMelissa Bersanelli, Letizia Gnetti, Augusto Vaglio, et al.
Immunotherapy|September 16, 2020
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapyMelissa Bersanelli, Teresa Zielli, Fabiana Perrone, et al.
Diagnostics (Basel, Switzerland)|February 11, 2023
The Role of CT Imaging in Characterization of Small Renal MassesMaria Vittoria Bazzocchi, Carlotta Zilioli, Vita Ida Gallone, et al.
Cancer Immunology, Immunotherapy : CII|September 26, 2009
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancerRodolfo Passalacqua, Carlo Buzio, Sebastiano Buti, et al.
Current Urology|August 11, 2020
Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell CarcinomaAlessio Cortellini, Sebastiano Buti, Melissa Bersanelli, et al.
Cancer Treatment and Research Communications|May 10, 2025
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumabGiulia Claire Giudice, Sara Elena Rebuzzi, Giulia Mazzaschi, et al.
Immunotherapy|June 9, 2018
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumabFrancesco Facchinetti, Michele Veneziani, Sebastiano Buti, et al.
Journal of Clinical Medicine|May 9, 2020
Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter AnalysisGiuseppe Lamberti, Maria Pia Brizzi, Sara Pusceddu, et al.
Anticancer Research|February 27, 2022
Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?Chiara Ciccarese, Roberto Iacovelli, Sebastiano Buti, et al.
Pageof 34

Showing results (151-160 of 336) with videos related to

Sort By:
Pageof 34
European Urology Oncology|August 13, 2023
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysisCarlo Messina, Emilio Francesco Giunta, Alessio Signori, et al.
Acta Bio-Medica : Atenei Parmensis|January 8, 2020
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumabMelissa Bersanelli, Letizia Gnetti, Augusto Vaglio, et al.
Immunotherapy|September 16, 2020
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapyMelissa Bersanelli, Teresa Zielli, Fabiana Perrone, et al.
Diagnostics (Basel, Switzerland)|February 11, 2023
The Role of CT Imaging in Characterization of Small Renal MassesMaria Vittoria Bazzocchi, Carlotta Zilioli, Vita Ida Gallone, et al.
Cancer Immunology, Immunotherapy : CII|September 26, 2009
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancerRodolfo Passalacqua, Carlo Buzio, Sebastiano Buti, et al.
Current Urology|August 11, 2020
Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell CarcinomaAlessio Cortellini, Sebastiano Buti, Melissa Bersanelli, et al.
Cancer Treatment and Research Communications|May 10, 2025
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumabGiulia Claire Giudice, Sara Elena Rebuzzi, Giulia Mazzaschi, et al.
Immunotherapy|June 9, 2018
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumabFrancesco Facchinetti, Michele Veneziani, Sebastiano Buti, et al.
Journal of Clinical Medicine|May 9, 2020
Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter AnalysisGiuseppe Lamberti, Maria Pia Brizzi, Sara Pusceddu, et al.
Anticancer Research|February 27, 2022
Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?Chiara Ciccarese, Roberto Iacovelli, Sebastiano Buti, et al.
Pageof 34